Calidi Biotherapeutics
CLDI
31 hedge funds and large institutions have $523K invested in Calidi Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
3% more funds holding
Funds holding: 30 → 31 (+1)
0.03% less ownership
Funds ownership: 0.06% → 0.03% (-0.03%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
66% less capital invested
Capital invested by funds: $1.53M → $523K (-$1.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
CPR Investments
Rochester,
Michigan
|
+$130K |
| 2 |
RCI
RS Crum Inc
Newport Beach,
California
|
+$67.3K |
| 3 |
DIM
Delta Investment Management
San Francisco,
California
|
+$53.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$33.5K |
| 5 |
HF
HRT Financial
New York
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$141K |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
-$123K |
| 3 |
SAMC
Spectrum Asset Management (California)
Newport Beach,
California
|
-$94.1K |
| 4 |
AMH
Apollo Management Holdings
New York
|
-$70.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$60.5K |
CLDI Hedge Fund Activity: Q2 2024 in Review
31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2024, worth a combined $523K — down 66% from $1.53M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLDI positions and 9 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.
The largest buyer was CPR Investments, adding an estimated $130K. The largest seller was Meteora Capital, exiting entirely with an estimated $141K sold.
- 31 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2024, up from 30 in Q1 2024.
- Funds reported $523K of Calidi Biotherapeutics stock for Q2 2024, down 66% quarter-over-quarter.
- 10 funds opened new Calidi Biotherapeutics positions in Q2 2024 and 9 closed out, a net change of +1 holder.
- The largest Calidi Biotherapeutics buyer in Q2 2024 was CPR Investments, an estimated $130K added.
- The largest Calidi Biotherapeutics seller in Q2 2024 was Meteora Capital, an estimated $141K sold.
Based on aggregated 13F filings for Q2 2024.